Clinical Trial

A Multi-part Study of ALG-000184 to Evaluate Safety, Tolerability, Pharmacokinetics and Drug-drug Interaction Potential After Single and Multiple Doses in Healthy Volunteers

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated February 3, 2025 (before its estimated July 7, 2025 completion). Its status may not reflect the trial's current state.
Summary
This Phase 1 study consists of two parts, all conducted in healthy volunteers (HVs). In Part 1, the drug-drug interaction (DDI) potential of ALG-000184 will be explored with Itraconazole; participants will be assigned to receive multiple doses of ALG-000184 and Itraconazole over a two week period. In Part 2, the drug-drug interaction (DDI) potential of ALG-000184 will be explored with Carbamazepine; participants will be assigned to receive multiple doses of ALG-000184 and ascending doses of Carbamazepine over an 18 day period. The 2 parts may be conducted in parallel.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-11-01; most recent amendment 2025-01-30.
Status change: Not Yet Recruiting → Active, Not Recruiting 2025-01-30
Trial Details
NCT Number NCT06672900
Lead Sponsor Aligos Therapeutics
Conditions Healthy Volunteer
Enrollment 24 participants
Start Date 2025-01-09
Primary Completion 2025-07-07 (estimated)
Study Completion 2025-07-07 (estimated)
Updated on ClinicalTrials.gov 2025-02-03